GlassScriptPhysician profile
Diana Barratt
NPI 1427012129
$1,482.66
in general payments reported to CMS, 2019-2025
13 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.74 · 2022: $247 · 2023: $404 · 2024: $154 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $411.69 | 2025 | Kisunla |
| Eisai INC. | $248.92 | 2025 | |
| Abbvie INC. | $181.82 | 2023-2024 | Botox |
| Astrazeneca Pharmaceuticals LP | $138.05 | 2022-2023 | Brilinta |
| Abbott Laboratories | $129.95 | 2023 | Amplatzer Talisman |
| Emd Serono, INC. | $96.75 | 2022 | |
| Ceribell, INC. | $95.00 | 2023 | Ceribell Rapid Response Eeg |
| Novo Nordisk INC | $73.80 | 2024 | |
| Alexion Pharmaceuticals, INC. | $36.76 | 2022-2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $20.27 | 2023 | Hyqvia |
| Lundbeck LLC | $18.64 | 2022 | |
| Janssen Biotech, INC. | $17.74 | 2019 | |
| Genentech USA, INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Barratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.